| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.045 | 0.2 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | -0.072 | 0.2 |
| mRNA | IOX2 | GDSC1000 | pan-cancer | AAC | -0.045 | 0.2 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | 0.046 | 0.2 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | 0.074 | 0.2 |
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | 0.064 | 0.2 |
| mRNA | CAY10576 | CTRPv2 | pan-cancer | AAC | -0.052 | 0.2 |
| mRNA | HC-067047 | CTRPv2 | pan-cancer | AAC | -0.05 | 0.2 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | -0.067 | 0.2 |
| mRNA | IC-87114 | CTRPv2 | pan-cancer | AAC | -0.049 | 0.2 |